What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near

Transaction summary

Key questions

• What were the execution details regarding the terms of the sold shares?
  The transaction was carried retired successful aggregate tranches with prices ranging from $13.36 to $15.33, resulting successful a weighted mean execution terms of $14.80 per share.

• How does this merchantability acceptable into the insider's broader concern strategy?
  The merchantability was executed pursuant to a Rule 10b5-1 trading program adopted connected December 9, 2025, which allows insiders to diversify their portfolios done pre-scheduled transactions.

• What is the standard of the remaining equity presumption held by the insider?
  Following this 4% simplification successful nonstop holdings, Stuart Naylor retains 641,000 shares of MeiraGTx, which had a full marketplace worth of $9.39 cardinal based connected the July 7, 2026 adjacent of $14.66.

• What has been the caller marketplace discourse for MeiraGTx stock?
  At the clip of the transaction, MeiraGTx had realized a one-year instrumentality of 89%, with the banal priced astatine $13.89 arsenic of the July 6, 2026 marketplace close.

Company Overview

Company Snapshot

• MeiraGTx is simply a clinical-stage cistron therapy institution processing therapeutic solutions for superior illnesses, including inherited ocular diseases, xerostomia pursuing radiation attraction for caput and cervix cancers, and assorted degenerative and neurodegenerative disorders.

• The institution generates gross done its clinical-stage cistron therapy programs and improvement partnerships, with a concern exemplary focused connected advancing proprietary cistron therapy candidates done objective improvement toward commercialization.

• MeiraGTx targets patients suffering from superior familial and degenerative conditions, with superior absorption connected ophthalmology, oncology supportive care, and neurodegenerative illness markets.

MeiraGTx Holdings plc operates arsenic a clinical-stage biotechnology institution with a marketplace capitalization of $1.4 billion. The institution has demonstrated important momentum, with its banal appreciating 89% implicit the past year, reflecting capitalist assurance successful its cistron therapy pipeline. MeiraGTx's competitory positioning centers connected its proprietary cistron therapy level targeting high-unmet-need indications crossed aggregate therapeutic areas, though the institution remains successful objective improvement stages with antagonistic nett income reflecting emblematic early-stage biotech concern patterns.